M L Quan1,2,3, I A Olivotto2, N N Baxter4,5, C M Friedenreich2,3,6, K Metcalfe7, E Warner8, K MacLennan9, J E Stephen10, M R Akbari5,11, D Howell6, S Narod5,11. 1. Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB. 2. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB. 3. Department of Community Health Sciences, University of Calgary, Calgary, AB. 4. Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON. 5. Women's College Hospital, University of Toronto, Toronto, ON. 6. Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, AB. 7. Lawrence S. Bloomberg Faculty of Nursing, Alberta Health Services, Calgary, AB. 8. Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON. 9. Applied Health Research Centre (ahrc), Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON. 10. Clinical Neurosciences Program, Alberta Health Services, Calgary, AB. 11. Dalla Lana School of Public Health, University of Toronto, Toronto, ON.
Abstract
Introduction: The understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, breast cancer (bca) in younger women is limited. We present the rationale, design, and initial recruitment of Reducing the Burden of Breast Cancer in Young Women (ruby), a unique national prospective cohort study designed to examine the diagnosis, treatment, quality of life, and outcomes from the time of diagnosis for young women with bca. Methods: Over a 4-year period at 33 sites across Canada, the ruby study will use a local and virtual recruitment model to enrol 1200 women with bca who are 40 years of age or younger at the time of diagnosis, before initiation of any treatment. At a minimum, comprehensive patient, tumour, and treatment data will be collected to evaluate recurrence and survival. Patients may opt to complete patient-reported questionnaires, to provide blood and tumour samples, and to be contacted for future research, forming the core dataset from which 4 subprojects evaluating genetics, lifestyle factors, fertility, and local management or delivery of care will be performed. Summary: The ruby study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected with respect to young women with bca from the time of diagnosis, enabling research unique to that population now and into the future. This research model could be used for other oncology settings in Canada. 2020 Multimed Inc.
Introduction: The understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, breast cancer (bca) in younger women is limited. We present the rationale, design, and initial recruitment of Reducing the Burden of Breast Cancer in Young Women (ruby), a unique national prospective cohort study designed to examine the diagnosis, treatment, quality of life, and outcomes from the time of diagnosis for young women with bca. Methods: Over a 4-year period at 33 sites across Canada, the ruby study will use a local and virtual recruitment model to enrol 1200 women with bca who are 40 years of age or younger at the time of diagnosis, before initiation of any treatment. At a minimum, comprehensive patient, tumour, and treatment data will be collected to evaluate recurrence and survival. Patients may opt to complete patient-reported questionnaires, to provide blood and tumour samples, and to be contacted for future research, forming the core dataset from which 4 subprojects evaluating genetics, lifestyle factors, fertility, and local management or delivery of care will be performed. Summary: The ruby study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected with respect to young women with bca from the time of diagnosis, enabling research unique to that population now and into the future. This research model could be used for other oncology settings in Canada. 2020 Multimed Inc.
Authors: Shoshana M Rosenberg; Karen Sepucha; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Meghan E Meyer; Lidia Schapira; Steven E Come; Virginia F Borges; Mehra Golshan; Eric P Winer; Ann H Partridge Journal: Ann Surg Oncol Date: 2015-05-01 Impact factor: 5.344
Authors: Frances C Wright; Nicole J Look Hong; May Lynn Quan; Kaitlyn Beyfuss; Sara Temple; Andrea Covelli; Nancy Baxter; Anna R Gagliardi Journal: Ann Surg Date: 2018-02 Impact factor: 12.969
Authors: A C Voogd; M Nielsen; J L Peterse; M Blichert-Toft; H Bartelink; M Overgaard; G van Tienhoven; K W Andersen; R J Sylvester; J A van Dongen Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Sylvie Bérubé; Louise Provencher; Jean Robert; Simon Jacob; Nicole Hébert-Croteau; Julie Lemieux; Thierry Duchesne; Jacques Brisson Journal: Breast Cancer Res Treat Date: 2007-02-01 Impact factor: 4.872
Authors: Ellen Copson; Bryony Eccles; Tom Maishman; Sue Gerty; Louise Stanton; Ramsey I Cutress; Douglas G Altman; Lorraine Durcan; Peter Simmonds; Gill Lawrence; Louise Jones; Judith Bliss; Diana Eccles Journal: J Natl Cancer Inst Date: 2013-05-30 Impact factor: 13.506
Authors: Jeffrey Q Cao; Pauline T Truong; Ivo A Olivotto; Robert Olson; Genevieve Coulombe; Mira Keyes; Lorna Weir; Karen Gelmon; Vanessa Bernstein; Ryan Woods; Caroline Speers; Scott Tyldesley Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-03 Impact factor: 7.038
Authors: Doris M Howell; Kelly Metcalfe; Shiying Kong; Joanne Stephen; Ivo A Olivotto; Nancy Baxter; Christine M Friedenreich; Ellen Warner; Mohammed Reza Akbari; Kristine McBain; Steven Narod; May Lynne Quan Journal: Breast Cancer Res Treat Date: 2022-04-24 Impact factor: 4.872
Authors: Carlos A Carmona; Samantha Yee; Maureen Seminsky; Karen Glass; Shu Foong; Eli Lipson; Nancy N Baxter; Christine M Friedenreich; Kelly Metcalfe; Susan Isherwood; Mohammad R Akbari; Steven Narod; May Lynn Quan; Ellen Warner Journal: Ann Surg Oncol Date: 2022-01-09 Impact factor: 5.344